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Background: Autotransporters form a large family of outer membrane proteins specifying diverse biological traits
of Gram-negative bacteria. In this study, we report the identification and characterization of a novel autotransporter
gene product of Burkholderia mallei (locus tag BMA1027 in strain ATCC 23344).
Results: Database searches identified the gene in at least seven B. mallei isolates and the encoded proteins were
found to be 84% identical. Inactivation of the gene encoding the autotransporter in the genome of strain ATCC
23344 substantially reduces adherence to monolayers of HEp-2 laryngeal cells and A549 type II pneumocytes, as
well as to cultures of normal human bronchial epithelium (NHBE). Consistent with these findings, expression of the
autotransporter on the surface of recombinant E. coli bacteria increases adherence to these cell types by 5–7 fold.
The gene specifying the autotransporter was identified in the genome of 29 B. pseudomallei isolates and disruption
of the gene in strain DD503 reduced adherence to NHBE cultures by 61%. Unlike B. mallei, the mutation did not
impair binding of B. pseudomallei to A549 or HEp-2 cells. Analysis of sera from mice infected via the aerosol route
with B. mallei and B. pseudomallei revealed that animals inoculated with as few as 10 organisms produce antibodies
against the autotransporter, therefore indicating expression in vivo.
Conclusions: Our data demonstrate that we have identified an autotransporter protein common to the pathogenic
species B. mallei and B. pseudomallei which mediates adherence to respiratory epithelial cells and is expressed
in vivo during the course of aerosol infection.Background
Autotransporter proteins are the largest known family of
virulence factors expressed by Gram-negative bacteria and
play prominent roles in processes such as invasion [1],
serum resistance [2,3], phospholipolysis [4-6], cytotoxicity
[7], adherence [8,9], survival within eukaryotic cells [10],
intracellular motility [11], cell-to-cell aggregation [12,13],
and biofilm formation [14,15]. These molecules display
conserved structural features including an N-terminal
surface-exposed domain responsible for the biological func-
tion and a hydrophobic C-terminus that tethers the auto-
transporter to the outer membrane (OM). Based on the
structure of the C-terminus, autotransporters can be classi-
fied as conventional or oligomeric [16-21]. The C-terminus* Correspondence: elafon10@uga.edu
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article, unless otherwise stated.of conventional autotransporters consists of ~300 amino
acids (aa) forming 10–12 antiparallel β-strands, while that
of oligomeric autotransporters is substantially shorter (~70
aa) and specifies only 4 β-strands. Because of their struc-
ture and role in virulence, autotransporters are attractive
targets for developing countermeasures against pathogenic
organisms. Large portions of autotransporters are located
on the bacterial surface and therefore readily accessible for
recognition by the immune system. Additionally, autotran-
sporters play important roles in pathogenesis, thus target-
ing them may hinder the ability to cause disease. This
hypothesis is supported by several studies demonstrating
the effectiveness of autotransporter-based countermea-
sures. For example, immunization with Neisseria meningi-
tidis NadA elicits antibodies (Abs) binding to the bacterial
surface and promoting complement-mediated killing
[22,23], which is key to protection against this organ-
ism. Antibodies against Haemophilus influenzae Haptral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with Hap protects mice in nasopharyngeal colonization
studies [24,25]. Vaccination with the Proteus mirabilis
autotransporter cytotoxin Pta yields Abs that not only
reduce bacterial burden in a murine urinary tract infec-
tion model, but also neutralize the cytotoxic activity of
Pta for bladder cells [26]. Moreover, Bordetella pertussis
Pertactin, an autotransporter adhesin, is a component
of licensed vaccines for whooping cough (http://www.
cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf ).
Burkholderia mallei and Burkholderia pseudomallei are
closely related Gram-negative organisms for which devel-
oping efficacious countermeasures is highly desirable. Both
species are classified as Tier 1 agents by the U.S. Federal
Select Agent Program because of concerns regarding their
use as bioweapons, especially since B. mallei has been uti-
lized in this manner on more than one occasion [27-31].
Burkholderia mallei is a host-adapted pleomorphic cocco-
bacillus that does not persist in the environment outside
of its natural equine reservoir. The bacterium causes the
highly contagious zoonotic disease glanders, which primar-
ily affects horses, and is endemic to parts of Asia, Africa,
South America and the Middle East [27,32-38]. In
humans, infection typically occurs via the cutaneous or
aerosol route upon contact with infected animals. Clinical
manifestations include fever, pneumonia, necrosis of the
trachea and bronchi, bacteremia, and dissemination of
B. mallei to organs where it causes necrotizing abscesses.
Burkholderia pseudomallei is a saprophyte of wet soils and
is endemic to countries bordering the equator. The organ-
ism can infect most mammals and causes the disease meli-
oidosis in humans, a febrile illness that varies greatly in its
clinical presentation. Disease states range from flu-like
malaise to septicemia, chronic abscess formation in deep
tissues, or bacteremic pneumonia [33,39-45]. Infection is
generally acquired by percutaneous inoculation, ingestion
and inhalation of aerosols, and the risk of contracting dis-
ease is proportionate to the concentration of B. pseudo-
mallei in soil. Burkholderia pseudomallei is a leading
cause of sepsis and bacteremic pneumonia in Southeast
Asia and Australia, and melioidosis is increasingly recog-
nized as an emerging infectious diseases in many tropical
regions of the world [40,46,47].
Glanders and melioidosis have high mortality rates
(up to 50%) despite aggressive antimicrobial therapy. The
recommended treatment involves the use of ceftazidime
and meropenem (intensive phase) and TMP-SMX and co-
amoxiclav (eradication phase) for several months [48]. Re-
sponse to treatment is slow and eradication of the agents
is difficult, often resulting in protracted alternating bouts
of remission and exacerbation. There are no vaccines
available to protect against either Burkholderia species.
Clearly, there is a need to identify and characterize targets
for developing countermeasures for these organisms. Thegenomes of B. mallei and B. pseudomallei have been re-
ported to encode multiple autotransporters [49-51]. In this
study, we examined one of these gene products and evalu-
ated it role in adherence in vitro and virulence in a mouse
aerosol model of infection.
Results
Identification of a gene encoding a potential
autotransporter adhesin shared by B. mallei and
B. pseudomallei
Comparative sequence analyses identified a gene prod-
uct in the published genome of B. mallei strain ATCC
23344 (locus tag # BMA1027) that resembles the adhe-
sins Yersinia enterocolitica YadA [2,21,52], Moraxella cat-
arrhalis Hag [8,53,54], B. pseudomallei BoaA and BoaB
[55], and B. mallei BoaA [55]. These molecules belong to
the oligomeric coiled-coil adhesin (Oca) sub-family of
oligomeric autotransporter proteins and have a character-
istic modular organization consisting of: (i) a surface-
exposed region specifying adhesive properties termed
passenger domain, (ii) a short linker region predicted to
form an α helix, and (iii) a hydrophobic C-terminus com-
posed of four β-strands anchoring the autotransporter in
the OM designated transporter domain [16,19-21]. As
shown in Figure 1A, BMA1027 is predicted to possess
these structural features.
Searches using the Pfam database revealed that the
region encompassing aa 936–1012 of BMA1027 shows
similarity to a YadA anchor domain (PF3895.10; expect
value of 6.3e−22), which is present in most Oca and de-
scribed as important for oligomerization and targeting
autotransporters to the OM. Pfam searches also indi-
cated that BMA1027 contains four YadA stalk domains
(PF05662, formerly designated HIM; expect values ran-
ging from 2.2e−4 to 1.5e−9; grey crosses in Figure 1A).
This motif is associated with invasins and haemaggluti-
nins and is present in YadA as well as Hag [2,8,52,53].
YadA contains one stalk domain, which has been shown
to be necessary for protein stability and adhesive proper-
ties. Further sequence analysis revealed that the passen-
ger domain of BMA1027 specifies repeated aa motifs, a
trait noted in several oligomeric autotransporters includ-
ing YadA [2,52], Hag [8,53], BoaA and BoaB [55], the B.
pseudomallei biofilm factor BbfA [56], and the M. ca-
tarrhalis UspA1, UspA2, and UspA2H proteins [57-60].
As illustrated in Figure 1A, the passenger domain of
BMA1027 contains nine copies of the 5-mer SLSTS (red
triangles) and several repeated elements beginning with
residues NSTA (colored boxes). Additional characteris-
tics of the predicted protein are listed in Table 1.
The published genomic sequence of the B. pseudomallei
strain K96243 was found to specify a BMA1027 ortholog
(locus tag # BPSL1631, Figure 1B) that is 89% identical to
that of B. mallei ATCC 23344. The BMA1027 ortholog
Figure 1 Structural features of BMA1027 and orthologous gene products. Different regions of the protein encoded by B. mallei ATCC 23344
BMA1027 (A), B. pseudomallei K96243 BPSL1631 (B) and the B. pseudomallei DD503 BMA1027 ortholog (C) are depicted with the positions of
residues defining selected domains. Transporter domains (OM anchors) and helical linkers were identified using the PSIPRED secondary structure
prediction algorithm. The colored boxes, red triangles, and grey crosses show the relative position and number of repeated aa motifs.
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our laboratory, DD503, and was predicted to encode a
protein that is 97% and 87% identical to that of B. pseudo-
mallei K96243 and B. mallei ATCC 23344, respectively
(Figure 1C). Database searches with the NCBI genomicTable 1 Characteristicsa of BMA1027 orthologous genes and





ATCC 23344 BMA1027 1,012
aSequence analyses were performed using Vector NTI (Life Technologies™) and onli
bGenomic sequences are available through the NCBI genomic BLAST service.
cThe putative signal sequence cleavage sites were determined using the SignalP 4.1
*The B. pseudomallei strain DD503 is a derivative of isolate 1026b in which the Amr
construction [61]. The BMA1027 orthologs of strains DD503 and 1026b are identicaBLAST service also identified orthologs in several B. pseu-
domallei and B. mallei isolates. Seven B. mallei and
twenty-nine B. pseudomallei strains for which sequences
are available through the service were found to have the
gene. Characteristics of these ORFs are listed in thetheir encoded products




ne tools available through the ExPASy Bioinformatics Resources Portal.
server.
AB-OprA antibiotic efflux pump has been deleted to facilitate mutant
l (confirmed by nucleotide sequence analysis, data not shown).
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identical and differ primarily in the number and/or ar-
rangement of SLST repeats, YadA stalk domains, and/or
NSTA elements in their passenger domains. Based on
these results, we conclude that BMA1027 orthologs are
well-conserved gene products shared by B. mallei and B.
pseudomallei. While preparing this article, Campos and
colleagues published a report in which they functionally
characterized autotransporter genes specified by the B.
pseudomallei strain 1026b [51]. One of these molecules
corresponds to the BMA1027 ortholog (locus tag #
BP1026B_1575), which the authors designated bpaC.
Henceforth, BMA1027 and orthologs will be referred to as
BpaC.
Expression and functional properties of the BpaC protein
in E. coli
Because of sequence and structural similarities to known
bacterial adhesins, we speculated that BpaC mediates
adherence to epithelial cells. To test this hypothesis, the
bpaC gene of B. pseudomallei DD503 was cloned and
expressed in the E. coli strain EPI300. This organism
does not adhere well to epithelial cells [8,53,55,62] and
therefore provides a suitable heterologous genetic back-
ground to study the adherence properties of BpaC. ToFigure 2 Analysis of E. coli recombinant strains. Panel A: Whole cell lys
analyzed by western blot with Abs against BpaC. Lane 1, E. coli (pCC1.3); lan
Panel B: Non-permeabilized E. coli strains were fixed onto glass slides and f
Bacteria were visualized by microscopy using a Zeiss LSM 510 Meta confoc
strains were incubated with epithelial cells for 3-hr. Cells were then washed
plates to enumerate bound bacteria. The results are expressed as the mean
epithelial cells. Asterisks indicate that the increased adherence of E. coli (pCCb
statistically significant (P value shown in parentheses). Adherence assays wereverify protein expression, whole cell lysates were pre-
pared from E. coli EPI300 harboring the plasmid pCC1.3
(control) or pCCbpaC (specifies B. pseudomallei DD503
bpaC) and analyzed by western blot. Figure 2A shows
that α-BpaC Abs (directed against aa 392–1098, part
of surface-exposed passenger domain) react specifically
with a band of 100-kDa in E. coli expressing the bpaC
gene (lane 2), which is consistent with the predicted mo-
lecular mass of the gene product (Table 1). The Abs also
specifically reacted with an antigen of high molecular
weight (≥250 kDa), which likely corresponds to an oli-
gomeric form of BpaC. Immunofluorescence-labeling of
non-permeabilized E. coli cells was used to demonstrate
that BpaC is displayed on the surface of recombinant bac-
teria. As shown in Figure 2B, E. coli carrying pCCbpaC is
labeled by α-BpaC Abs while recombinant bacteria har-
boring the control plasmid pCC1.3 are not. Staining of
nucleic acids with DAPI verified that equivalent numbers
of bacteria were examined.
Quantitative adherence assays revealed that E. coli ex-
pressing BpaC binds to HEp-2 (laryngeal) and A549 (lung)
human epithelial cells at levels 7- and 5-fold greater than
bacteria carrying pCC1.3, respectively (Figure 2C). BpaC
expression was also found to increase adherence by 7-fold
to normal human bronchial epithelium (NHBE) culturedates were resolved by SDS-PAGE, transferred to PVDF membranes and
e 2, E. coli (pCCbpaC). MW markers are shown to the left in kilodaltons.
luorescently-labeled with DAPI (blue) and with α-BpaC Abs (red).
al system. Representative microscopic fields are shown. Panel C: E. coli
to remove unbound bacteria, lysed, diluted and spread onto agar
percentage (±standard error) of inoculated bacteria attached to
paC), compared to that of E. coli carrying the control plasmid pCC1.3, is
performed in duplicate on at least 4 independent occasions.
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represent an environment similar to the airway lumen
in vivo [54,63,64]. These results demonstrate that BpaC
mediates adherence to respiratory epithelial cells. Burkhol-
deria pseudomallei and B. mallei are facultative intracellu-
lar bacteria that replicate within several eukaryotic cell
types. Moreover, autotransporter adhesins frequently per-
form additional functions including invasion [1], intracel-
lular motility [11], and survival inside host cells [10]. For
these reasons, we examined the ability of E. coli expressing
BpaC to invade epithelial cells and survive within murine
macrophages. The results of these experiments indicated
that BpaC does not substantially increase invasion of
epithelial cells, phagocytosis of recombinant bacteria by
J774A.1 murine macrophages, or survival inside these im-
mune cells (data not shown).
In vitro characterization of B. mallei and B. pseudomallei
mutant strains
To study the functional properties of the bpaC gene
product in Burkholderia, we constructed isogenic bpaC
mutants of B. pseudomallei DD503 and B. mallei ATCC
23344. Whole cell lysates and sarkosyl-insoluble OMFigure 3 Adherence of B. mallei and B. pseudomallei strains to human
adherence of B. pseudomallei (Bp) DD503 and B. mallei (Bm) ATCC 23344 to
and cultures of NHBE (panels C and F) was measured in duplicate on at lea
3-hr. Cells were then washed to remove unbound bacteria, lysed, diluted a
results are expressed as the mean percentage (±standard error) of inoculat
difference between the adherence of the bpaC KO mutant and that of theproteins were prepared from these strains and analyzed
by western blot to verify lack of BpaC expression in the
mutants. However, α-BpaC Abs did not react with pro-
tein preparations of parent or mutant strains (data not
shown). Other methods such as immunoprecipitation
and immunofluorescence-labeling also failed to detect
BpaC expression. These results indicate that the bpaC
gene is expressed at very low levels under the laboratory
growth conditions we used to propagate the organisms.
Because adherence assays with recombinant bacteria
revealed that BpaC expression increases the binding of
E. coli to NHBE cultures and monolayers of A549 and
HEp-2 cells (Figure 2C), we compared the ability of
Burkholderia parent and bpaC mutant strains to attach
to these respiratory cells. Figure 3C shows that inactiva-
tion of the bpaC gene in B. pseudomallei DD503 affects
adherence to NHBE cultures, reducing levels by 61%.
The B. pseudomallei mutant bound to A549 and HEp-2
cells at wild-type levels. The bpaC mutation significantly
impaired the ability of B. mallei ATCC 23344 to attach
to A549 cells (66% reduction, Figure 3D), HEp-2 mono-
layers (72% reduction, Figure 3E), and NHBE cultures
(66% reduction, Figure 3F). These results demonstraterespiratory epithelial cells. The effect of a bpaC mutation on the
monolayers of A549 (panels A and D) and HEp-2 (panels B and E) cells
st 3 separate occasions. Strains were incubated with epithelial cells for
nd spread onto agar plates to enumerate bound bacteria. The
ed bacteria adhering to epithelial cells. Asterisks indicate that the
parent strain is statistically significant (P value shown in parentheses).
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of B. mallei and B. pseudomallei to epithelial cells de-
rived from the human respiratory tract.
As stated earlier, autotransporter adhesins often perform
multiple biological functions including invasion [1] and
survival within host cells [10]. In addition, B. pseudomallei
and B. mallei are facultative intracellular pathogens that
effectively replicate inside professional phagocytic cells.
Therefore, we measured the ability of Burholderia mutant
and parent strains to invade epithelial cells (A549 and
HEp-2) and replicate within J774A.1 murine macrophages.
The results of these experiments indicated that the bpaC
mutation does not cause a defect in invasion of epithelial
cells, phagocytosis of recombinant bacteria by J774A.1
murine macrophages, or growth inside these cells (data
not shown). The bpaC mutants did not show defects in
resistance to the bactericidal activity of normal human
serum (data not shown), which is another biological func-
tion commonly associated with Oca autotransporters
[2,3,19,65,66].
Virulence of B. mallei and B. pseudomallei mutant strains
and BpaC expression in vivo
To determine whether BpaC contributes to virulence,
we calculated the median lethal dose (LD50) of B. pseu-
domallei and B. mallei mutant strains in a mouse modelTable 2 Median lethal dose determination of B. mallei and B.
Organism Strain Inoculating dose




















amice were monitored daily for clinical signs of illness/morbidity for 10 days post-in
bmice were monitored daily for clinical signs of illness/morbidity for 6 days post-inoof aerosol infection. The model entails the use of a
Microsprayer® to deliver bacteria directly into the mur-
ine lungs [67]. The device generates aerosol particles
from the tip of a bent, 23-gauge nebulizing tube attached
to a high-pressure stainless steel syringe that contains
bacteria. BALB/c mice were anesthetized and placed in a
custom-designed acrylic holder inside a Class II Bio-
safety cabinet. A modified pediatric otoscope equipped
with a light source was then used to introduce the nebu-
lizing tube portion of the Microsprayer® into the trachea
of animals, and 50-μL of bacterial suspension was
aerosolized into the lungs by pushing the plunger of the
high-pressure syringe. Following infection, mice were
observed daily for clinical signs of illness and morbidity.
As shown in Table 2, the bpaC mutation did not have
an impact on the LD50 values of B. mallei ATCC 23344
or B. pseudomallei DD503. Tissues (i.e. lungs, spleen,
liver) from mice that survived the acute phase of infec-
tion did not show differences in bacterial loads (data not
shown). Based on these results, we conclude that the
bpaC mutation does not affect the virulence of B. mallei
ATCC 23344 or B. pseudomallei DD503 via the aerosol
route of infection.
To gain insight into the immune response to BpaC
during infection, we tested sera from mice that survived
aerosol challenge with B. mallei ATCC 23344 andpseudomallei WT and mutant strains
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of Abs against the adhesin. Panels A and B in Figure 4
show that mice inoculated with doses as low as 10 CFU
produced Abs against BpaC, which in turn demon-
strates that this autotransporter is expressed by both
B. mallei and B. pseudomallei during infection.Figure 4 ELISA with sera from mice that survived aerosol
challenge with various doses of B. pseudomallei 1026b and
B. mallei ATCC 23344. Serum samples were serially diluted and
placed in duplicate wells of plates coated with purified His-tagged
protein encompassing aa 392–1068 of B. pseudomallei 1026b BpaC.
Goat α-mouse Abs conjugated to HRP were used as secondary Abs.
The y-axis shows absorbance at a wavelength of 650 nm, which is
indicative of antibody binding to antigens coating the plates. The
x-axis represents two-fold dilutions of sera starting at 1:100 to
1:12,800. The results are expressed as the mean absorbance
(±standard deviation). Closed circles show sera from mice inoculated
with 104 B. pseudomallei bacteria (panel A). Open circles show sera
from mice infected with 103 organisms (panels A and B). Open
triangles show sera from mice inoculated with 102 bacteria
(panels A and B). Closed diamonds show sera from mice infected
with 101 CFU of B. mallei ATCC 23344 (panel B). Blue squares
represent sera from control mice that were inoculated with 50 μL of
PBS using the Microsprayer (panels A and B). Of note, sera from
mice that survived acute infection by B. pseudomallei and B. mallei
are described elsewhere [67].Discussion
The genome of B. mallei ATCC 23344 has been reported
to specify eight autotransporter gene products [49] and of
these, only BoaA (adhesin, [55]) and BimA (intracellular
motility protein, [11,68]) have been functionally character-
ized. Both are classified as oligomeric autotransporters be-
cause they possess a short C-terminal transporter module
predicted to form 4 β-strands, which anchor the molecules
on the bacterial surface. In the present study, we charac-
terized a third B. mallei ATCC 2334 oligomeric autotran-
sporter, BpaC (BMA1027). Comparative sequence analyses
indicate that the gene product is conserved among B. mal-
lei isolates (see Additional files 1 and 2) and resembles
members of the Oca (oligomeric coiled-coil adhesin) sub-
family of oligomeric autotransporter proteins [16,19-21].
Consistent with this, inactivation of bpaC in the genome
of B. mallei ATCC 23344 reduces adherence to mono-
layers of A549 (lung) and HEp-2 (larynx) cells grown
in submerged cultures (Figure 3D and E, respectively).
Though these cells are relevant to aerosol infection by B.
mallei, they lack key features of the airway mucosa such as
cilia and mucociliary activity. Ciliated cells contribute to
preventing colonization of the respiratory tract by patho-
genic agents by moving secretions (and trapped organ-
isms) toward the laryngopharynx for expectoration or
swallowing to the stomach (where the acidic pH neutral-
izes organisms). For these reasons, we measured the
adherence of the B. mallei bpaC mutant to cultures of
NHBE grown in an air-liquid interface system. These cul-
tures mimic the structure and function of the airway mu-
cosa as they form a pseudostratified epithelium with tight
junctions, contain ciliated and mucus-producing goblet
cells, and display mucociliary activity [63,64]. Quantitative
assays using this system revealed that adherence of the
bpaCmutant was reduced by 66% (Figure 3F).
Orthologs of BpaC were identified in 29 B. pseudomallei
isolates (see Additional files 1 and 2). The genome of some
of these strains has not been completed, resulting in the
passenger domain and transporter module of BpaC seem-
ingly specified by two different ORFs (e. g. B7210, 112,
BPC006, 354e). Inactivation of bpaC in the genome of the
B. pseudomallei strain DD503 caused a 2.6-fold reduction
in adherence to NHBE cultures (Figure 3C), which is con-
sistent with the phenotype of the B. mallei bpaC mutant
(Figure 3F). However, the bpaC mutation did not affect
adherence of B. pseudomallei to A549 or HEp-2 cells
(Figure 3A and B, respectively). One possible explanation
for this lack of effect is that other adhesins expressed by
the B. pseudomallei DD503 bpaC mutant provide a high
background of adherence to A549 and HEp-2 monolayers.
For instance, BoaA and BoaB have been shown to mediate
binding of B. pseudomallei DD503 to HEp-2 and A549
cells [55]. Moreover, it was recently demonstrated that the
B. pseudomallei gene products BpaA, BpaB, BpaD, BpaE
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The genes encoding these molecules are present in the
genome of strain DD503.
While preparing this article, Campos and colleagues
published a study in which they demonstrate that BpaC
is an adhesin for A549 cells [51]. The authors reported
that a mutation in the bpaC gene of B. pseudomallei
strain 340 causes an ~ 10-fold reduction in adherence.
These results are in contrast with our data showing that
a B. pseudomallei DD503 bpaC mutant binds to A549
cells at wild-type levels (Figure 3A). One possible ex-
planation for this phenotypic difference is that we
performed adherence assays using plate-grown bacteria,
and infected A549 cells for 3 hours before washing off
unbound B. pseudomallei and measuring cell-binding.
Campos et al. used overnight broth cultures to inoculate
A549 cells and infected monolayers for only 2 hours.
The method used to construct mutants might have im-
pacted the experimental outcome of adherence assays as
well. In the present study, an internal portion of the
bpaC ORF was replaced with a zeocin resistance marker
and this mutation was introduced in the genome of B.
pseudomallei DD503 via allelic exchange. In contrast,
the bpaC gene of B. pseudomallei strain 340 was dis-
rupted via co-integration of a large plasmid (~9-kb) in
the genome [51]. It is unlikely that the strain back-
ground in which the mutations were constructed has
any effect on the phenotype of bpaC mutants since
strains DD503 [61] and 340 [69] are both antibiotic-
sensitive derivatives of the same clinical isolate, B. pseu-
domallei 1026b. Despite these differences, our data
constitute independent proof of the role of BpaC as an
adhesin. These results are substantiated by showing that
expression of BpaC on the surface of recombinant E. coli
bacteria increases adherence to NHBE, A549 and HEp-2
cells (Figure 2).
Given the phenotype of mutants in assays with NHBE
cultures and that adherence is a key step in pathogenesis
by most infectious agents, we expected the bpaC mutation
to reduce the virulence of B. mallei and/or B. pseudomal-
lei in a mouse model of aerosol infection. However, the re-
sults of our animal experiments indicate that the mutants
are as virulent as wild-type strains (Table 2). Presumably,
other adhesins expressed by the bpaC mutants provide
sufficient adherence to the murine airway mucosa to allow
colonization at wild-type levels and for the normal course
of disease to ensue. It is unlikely that the lack of pheno-
type we observed in vivo is due to non-expression of
BpaC. Though we discovered that B. pseudomallei DD503
and B. mallei ATCC 23344 do not produce detectable
amounts of BpaC under routine laboratory growth condi-
tions, ELISA with sera from mice that survived acute aero-
sol infection with the agents show that animals produce
Abs against the protein (Figure 4A and B). Moreover, serafrom horses with experimental glanders have been shown
to contain high antibody titers against BpaC [70]. These
results are particularly significant as horses are the natural
host and reservoir for B. mallei and arguably the most
relevant surrogate to study glanders. Together, these data
demonstrate that BpaC is expressed in vivo and elicits the
production of Abs during infection.
The infection model we used to examine the effect of
the bpaC mutation might have impacted the outcome of
virulence experiments. This hypothesis is supported by
the Campos et al. study in which they show that the
bpaC mutation reduces the ability of B. pseudomallei
strain 340 to disseminate and/or survive in the liver [51].
In these experiments, BALB/c mice were infected intra-
nasally with 500 CFU of the agent and bacterial loads in
tissues were determined 48 hours post-infection. In con-
trast, we inoculated BALB/c mice intratracheally using a
Microsprayer®, which nebulizes bacteria directly into the
lungs, infected animals with doses ranging from 102 to
105 CFU, and determined bacterial burden in survivors
6–10 days post-infection (Table 2). It is also known that
the choice of bacterial strains [71], inoculation route
[72], and animal background [73] can significantly affect
the course of disease by B. pseudomallei and B. mallei.
For example, the LD50 value of the same B. pseudomallei
isolate has been shown to differ by several orders of
magnitude in C57BL/6 mice and BALB/c mice [74].
Therefore, a complete understanding of the role of BpaC
in pathogenesis may require the use of multiple infection
models.
Conclusion
This study demonstrates that BpaC is an autotransporter
protein, which mediates adherence of B. mallei and B. pseu-
domallei to host cells that are relevant to pathogenesis by
the organisms. We show that BpaC is conserved among
isolates of both Burkholderia species, is expressed in vivo,
and elicits production of Abs during infection. Hence, BpaC
displays many properties of an important virulence factor
and potential target for developing countermeasures.
Though our animal experiments indicate that a mutation in
bpaC does not impact the virulence of B. mallei or B. pseu-
domallei, adherence to host surfaces is a key early step in
pathogenesis by most infectious agents. To accomplish this,
pathogenic organisms typically express multiple adhesins
to ascertain host colonization. It is likely that disruption of
multiple genes specifying adherence factors, including
bpaC, will result in decreased virulence and clarify the role
of the autotransporter in the pathogenesis of B. mallei and
B. pseudomallei. Continued investigation of BpaC will yield
important information regarding the complex biology and
virulence of these organisms, and may contribute to devel-
opment of comprehensive countermeasures targeting auto-
transporters and their roles in pathogenesis.
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Strains, plasmids, tissue culture cell lines and growth
conditions
The strains and plasmids used in this study are listed in
Table 3. For construction of the B. pseudomallei bpaCmu-
tant, Low Salt Luria Bertani (LSLB) agar (Teknova) supple-
mented with antibiotics was utilized as selective medium.
For all other experiments, B. pseudomallei was cultured
on Trypticase Soy Agar (BD) at 37°C. Brucella Agar (BD)
supplemented with 5% glycerol was used to grow Burkhol-
deria mallei at 37°C. Where indicated, antibiotics were
added to the culture media at the following concentra-
tions: 7.5 μg/mL (for B. mallei) and 100 μg/mL (for B.
pseudomallei) Polymixin B (MP Biomedicals), 7.5 μg/mL
(for B. mallei) and 50 μg/mL (for B. pseudomallei) kana-
mycin (MP Biomedicals), 7.5 μg/mL (for B. mallei) and
100 μg/mL (for B. pseudomallei) zeocin™ (Life Technolo-
gies™). Plate-grown bacteria (40-hr for B. mallei, 20-hr for
B. pseudomallei) were used for all experiments. For conju-
gative transfer of plasmids from E. coli to Burkholderia,
MgSO4 was added to culture media at a final concentra-
tion of 10 mM.
Escherichia coli was cultured at 37°C using LSLB sup-
plemented with 15 μg/mL chloramphenicol, 50 μg/mL
kanamycin, or 50 μg/mL zeocin, where indicated. ForTable 3 Strains and plasmids
Strain/plasmid Description
B. pseudomallei
DD503 Parental strain; polymixin B resistant, zeocin sensitive, ka
bpaC KO Isogenic bpaC mutant strain of DD503; polymixin B resi
B. mallei
ATCC 23344 Wild-type strain; polymixin B resistant, zeocin sensitive,
bpaC KO Isogenic bpaC mutant strain of ATCC 23344; polymixin
E. coli
EPI300 Cloning strain
TUNER™ Expression strain for purification of His-tagged BpaC
S17 Strain used for conjugational transfer of pKASbpaC.zeo
pCC1™ Cloning vector, chloramphenicol resistant
pCCbpaC pCC1 containing the B. pseudomallei DD503 bpaC gene
pCCbpaC.zeo pCCbpaC in which a zeocin resistance cassette was intr
chloramphenicol and zeocin resistant
pCC1.3 pCC1-based plasmid control, does not confer adherenc
pKAS46 Mobilizable suicide plasmid; kanamycin resistant
pKASbpaC.zeo pKAS46 containing the insert from pCCbpaC.zeo
pEM7ZEO Source of the zeocin resistance marker
pELHisBPSL1631-
BMA1027
Plasmid expressing aa 392–1068 of B. pseudomallei 102
duced in E. coli TUNER and used to purify His-tagged B
ments; chloramphenicol resistant.conjugation experiments, LSLB was supplemented with
10 mM MgSO4. For assays with E. coli clones carrying
pCC1-based plasmids, the CopyControl™ Induction So-
lution (epicentre® Illumina®) was added to LSLB as previ-
ously reported [9].
The cell lines HEp-2 (human laryngeal epithelium;
ATCC CCL-23), A549 (type II alveolar epithelium; ATCC
CCL85) and J774A.1 (murine macrophages; ATCC TIB-
67) were cultured as outlined by others [5,55]. Normal
human bronchial epithelium (NHBE; LONZA) was ex-
panded, cryopreserved and cultured in an air-liquid inter-
face system as previously described [54,63,64]. The apical
surface of the NHBE was exposed to air for a minimum of
3 weeks prior to use in adherence assays to ascertain
proper cellular differentiation and the development of
functional cilia.
Recombinant DNA methodology
Standard molecular biology techniques were performed
as described elsewhere [79]. Genomic DNA was purified
from Burkholderia using the Easy-DNA™ Kit (Life Tech-
nologies™). Plasmid DNA was isolated with the QIAprep
Spin Miniprep kit (QIAGEN). The Platinum® Pfx DNA
Polymerase (Life Technologies™) was used to amplify
the 3.8-kb bpaC gene of B. pseudomallei DD503 withReference
namycin sensitive (derived from clinical isolate 1026b) [61]
stant, zeocin resistant, kanamycin sensitive This study
kanamycin sensitive [75]




to B. pseudomallei and B. mallei [76]
epicentre®
Illumina®
, chloramphenicol resistant This study
oduced near the middle of the bpaC ORF; This study





6b BpaC fused to six N-terminal histidine residues, intro-
paC protein for antibody production and ELISA experi-
[67]
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GGT-3′) and P2 (5′-TGC GCG AAT CAA TCG AGA
TAC CCA-3′) and the PCR product was used as a tem-
plate in sequencing reactions. The amplicon was also
cloned in the vector pCC1™ using the CopyControl™
PCR cloning kit (epicentre® Illumina®), producing the
plasmid pCCbpaC (Table 3). The latter was sequenced
to determine that PCR did not introduce mutations
resulting in aa substitutions in the bpaC gene product.Construction of isogenic mutant strains of B. mallei and B.
pseudomallei
The plasmid pCCbpaC was digested with the enzyme
NsiI (New England BioLabs®, Inc.) to remove a 0.6-kb
fragment internal to the bpaC ORF, treated with the
End-It™ DNA End Repair Kit (epicentre® Illumina®), and
ligated with a 0.4-kb zeocin resistance cassette to yield
the construct pCCbpaC.zeo. This plasmid was restricted
with BamHI (New England BioLabs®, Inc.) and a 3.4-kb
fragment corresponding to the bpaC ORF disrupted by
the insertion of the zeocin resistance cassette was ex-
cised from an agarose gel, purified with the High Pure
PCR Product Purification kit (Roche Applied Science),
and treated with the End-It™ DNA End Repair Kit. This
blunt DNA fragment was then cloned in the suicide vec-
tor pKAS46. The resulting plasmid, designated pKASb-
paC.zeo, was introduced in the E. coli strain S17 by
electroporation, and subsequently transferred into B.
mallei ATCC 23344 or B. pseudomallei DD503 by con-
jugation, as previously reported [55,80]. Upon conjuga-
tion, Burkholderia colonies were selected for resistance
to zeocin. These putative mutants were then screened by
PCR using Platinum® Pfx DNA Polymerase with primers
P1 and P2. The primers yielded a PCR product of 3.8-kb
in the parent strains and a smaller amplicon of 3.6-kb in
bpaC mutants. The PCR products from mutant strains
were sequenced to verify proper allelic exchange and
successful disruption of bpaC.Nucleotide sequence and bioinformatic analyses
PCR products and plasmids were sequenced at the
University of Michigan Sequencing Core (http://seqcore.
brcf.med.umich.edu). Chromatograms were assembled using
the Sequencher® 5 software (Gene Codes Corporation).
Sequence analyses were performed using Vector NTI (Life
Technologies™) and the various online tools available
through the EsPASy Bioinformatics Resource Portal
(http://www.expasy.org). Signal sequence cleavage sites
were determined using the SignalP 4.1 server (http://www.
cbs.dtu.dk/services/SignalP). The B. mallei ATCC 23344
bpaC gene product (locus tag # BMA1027) was identified
by searching the genome of the organism for the pres-
ence of a YadA anchor domain (Pfam database numberPF3895.10) through the NCBI genomic BLAST service
using the blastp program (http://www.ncbi.nlm.nih.gov/
sutils/genom_table.cgi). The other bpaC gene products
described in this study were identified using the pre-
dicted aa sequence of the B. mallei ATCC 23344 BpaC
protein to search the genomes of the B. mallei and B.
pseudomallei strains available through the NCBI gen-
omic BLAST service utilizing the tblastn and blastp pro-
grams. Structural features of the BpaC proteins (helical
regions, hydrophobic β-strands) were identified with
the PSIPRED Protein Sequence Analysis Workbench
service (http://bioinf.cs.ucl.ac.uk/psipred/).
Experiments with epithelial cells and J774 murine
macrophages
Adherence, invasion, and intracellular survival assays
were performed as previously reported by our laboratory
[53-55]. Cells were inoculated with bacteria at a multi-
plicity of infection (MOI) of 100. Duplicate assays were
performed on at least 3 occasions. Statistical analyses
were performed using the Mann–Whitney test (Graph-
Pad Prism® 6 software) and P values < 0.05 are reported
as statistically significant.
Bactericidal assays
The method used to examine the effect of bpaC muta-
tions on the ability of Burkholderia to resist the bacteri-
cidal activity of complement is outlined elsewhere
[9,77,81]. We used final concentrations of 50% and 25%
serum in assays with B. pseudomallei and B. mallei,
respectively.
Protein preparations, western blot, purification of
recombinant BpaC protein, and antibody production
Sarkosyl-insoluble OM protein preparations were obtained
as described by Carlone et al. [82]. The methods used to
prepare whole cell lysates and perform western blot
experiments are described elsewhere [8,53,54,57,83,84].
His-tagged recombinant BpaC was obtained from cultures
of E. coli TUNER carrying the plasmid pELHisBPSL1631-
BMA1027, as previously outlined by our laboratory [67].
To obtain polyclonal Abs directed against BpaC, the
purified His-tagged protein was emulsified in Freund’s
adjuvants (SIGMA-ALDRICH®) and used to immunize
female BALB/c mice as reported by Lafontaine and
colleagues [85].
Immunofluorescence labeling of E. coli and microscopy
Expression of BpaC on the surface of E. coli recombinant
bacteria was visualized by immunofluorescence microscopy
as outlined by Balder et al. [55]. Briefly, paraformaldehyde-
fixed E. coli cells were spotted onto glass slides. These bac-
teria were probed with α-BpaC polyclonal Abs, followed by
incubation with a goat α-mouse antibody labeled with
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dye DAPI (Life Technologies™). Slides were examined by
microscopy using a Zeiss LSM 510 Meta confocal system.
ELISA
Duplicate wells of Immulon™ 2HB plates (Thermo Scien-
tific Nunc) were coated overnight at 4C° with 1 μg of
His-tagged BpaC. Excess unbound antigen was removed
by washing the wells with PBS + 0.05% Tween 20
(PBST), and the wells were then blocked with PBS +
0.05% containing 3% dry milk (blocking buffer) for
1 hour at room temperature. After washing with PBST,
the wells were probed overnight at 4°C with sera from
mice that survived acute aerosol infection with B. mallei
ATCC 23344 and B. pseudomallei 1026b [67] diluted in
blocking buffer. After this incubation, the wells were
washed with PBST and incubated overnight with a goat
α-mouse antibody conjugated to Horse Radish Peroxid-
ase (SouthernBiotech) diluted in blocking buffer. After
washing off the excess secondary antibody with PBST,
100 μL of the SureBlue™ TMB Microwell Peroxidase
Substrate (KPL) was added to the wells. Color develop-
ment, which is indicative of Abs binding to BpaC, was
measured spectrophotometrically by determining the ab-
sorbance of well contents at a wavelength of 650 nm.
Animal experiments
Female BALB/c mice (6–8 weeks of age) were purchased
from Frederick National Laboratory for Cancer Research.
The animals were anesthetized by injecting a dose of
250 mg/kg of 2,2,2 tribromoethanol (SIGMA-AL-
DRICH®) intraperitoneally. Once anesthetized, mice were
inoculated intratracheally with 50 μL of bacterial suspen-
sions using a Microsprayer® model I-1C (PennCentury™)
as previously reported by our laboratory [67]. Infected
animals were monitored twice daily. Humane end-points
were strictly observed. Mice exhibiting signs of moderate
to severe discomfort were euthanized. This was accom-
plished by anesthetizing the animals with 2,2,2 tribro-
moethanol followed by cervical dislocation, in accordance
with the AVMA Guidelines on euthanasia. Food and water
were provided ad libitum. Analgesics were not used as
they may have affected the experimental outcomes of the
studies. Survival data were analyzed using the Kaplan-
Meier method and the LD50 values were calculated
according to Reed and Muench [86].
Compliance and animal research ethic statements
All experiments with live B. pseudomallei and B. mallei
were performed inside a Class II Biosafety Cabinet in a
BSL3 laboratory and in compliance with the rules and
regulations of the U.S. Federal Select Agent Program.
The experiments were approved by the University of
Georgia’s Institutional Biosafety Committee (IBC).Animal experiments were carried out in strict accord-
ance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National
Institutes of Health. The experiments were approved by
the University of Georgia’s Institutional Animal Care
and Use Committee (IACUC). All efforts were made to
minimize animal suffering.
Additional files
Additional file 1: Comparison of the structural features specified by
B. pseudomallei and B. mallei bpaC gene products.
Additional file 2: Characteristicsa of BMA1027 orthologous genes
and their encoded products.
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